Department of Microbiology, Tzaneio General Hospital, Piraeus, Greece.
J Clin Microbiol. 2012 Nov;50(11):3747-50. doi: 10.1128/JCM.02037-12. Epub 2012 Aug 29.
We evaluated the Vitek2, Etest, and MIC Test Strip (MTS) methods of tigecycline susceptibility testing with 241 expanded-spectrum cephalosporin-resistant and/or carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii clinical isolates by using dry-form broth microdilution (BMD) as the reference method. The MIC(50/90)s were as follows: BMD, 1/4 μg/ml; Vitek2, 4/≥8 μg/ml; Etest, 2/4 μg/ml; MTS, 0.5/2 μg/ml. Vitek2 produced 9.1/21.2% major errors, Etest produced 0.4/0.8% major errors, and MTS produced no major errors but 0.4/3.3% very major errors (FDA/EUCAST breakpoints). Vitek2 tigecycline results require confirmation by BMD or Etest for multidrug-resistant pathogens.
我们评估了 241 株扩展谱头孢菌素耐药和/或碳青霉烯类耐药肠杆菌科和鲍曼不动杆菌临床分离株的替加环素药敏试验的 Vitek2、Etest 和 MIC 测试条（MTS）方法，以干粉肉汤微量稀释（BMD）作为参考方法。MIC（50/90）如下：BMD，1/4μg/ml；Vitek2，4/≥8μg/ml；Etest，2/4μg/ml；MTS，0.5/2μg/ml。Vitek2 产生 9.1/21.2%的主要错误，Etest 产生 0.4/0.8%的主要错误，MTS 没有产生主要错误，但产生 0.4/3.3%的非常大的错误（FDA/EUCAST 折点）。Vitek2 替加环素结果需要通过 BMD 或 Etest 对多药耐药病原体进行确认。
